FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony
Executive Summary
An upgrade to Abbott's Meridia riskmanagement program means FDA has taken action to strengthen warnings on four of seven drugs flagged by FDA Office of Drug Safety Associate Director David Graham, MD, during the Senate Finance Committee's hearing on Vioxx
You may also be interested in...
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor
Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said